红曲调脂汤治疗原发性高脂血症的疗效和安全性研究

Clinical efficacy and safety of Hongqu Tiaozhi Tang in the treatment of primary hyperlipidemia

目的观察红曲调脂汤治疗原发性高脂血症的临床效果。方法选取2022年8月至2023年4月江门市人民医院收治的94例原发性高脂血症患者作为研究对象,按随机数表法分为对照组和研究组各47例,对照组患者采用阿托伐他汀治疗,研究组患者采用红曲调脂汤治疗,均持续治疗4周。比较两组患者治疗后的临床疗效,治疗前及治疗结束时的甘油三酯、总胆固醇、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇水平,同时比较两组患者治疗期间的药物安全性和随访1年内心血管不良事件发生情况。结果研究组患者的临床治疗总有效率为95.74%,明显高于对照组的78.72%,差异有统计学意义(P<0.05);治疗前,两组患者的血脂水平比较差异无统计学意义(P>0.05);治疗后,两组患者的甘油三酯、总胆固醇、低密度脂蛋白胆固醇水平均下降,高密度脂蛋白胆固醇水平均升高,研究组患者的甘油三酯、总胆固醇、低密度脂蛋白胆固醇水平分别为(1.52±0.22)mmol/L、(4.03±0.55)mmol/L、(2.24±0.35)mmol/L,明显低于对照组的(1.86±0.35)mmol/L、(4.87±0.62)mmol/L、(2.87±0.39)mmol/L,高密度脂蛋白胆固醇水平为(1.42±0.13)mmol/L,明显高于对照组的(1.29±0.14)mmol/L,差异均有统计学意义(P<0.05);研究组患者的药物不良反应总发生率为6.38%,明显低于对照组的23.40%,差异有统计学意义(P<0.05);随访1年,研究组患者的心血管不良事件总发生率为8.51%,明显低于对照组的25.53%,差异有统计学意义(P<0.05)。结论红曲调脂汤治疗原发性高脂血症能够有效调节患者的血脂水平,降低心血管不良事件的发生率,临床治疗效果肯定且安全性较高。

Objective To observe the clinical efficacy of Hongqu Tiaozhi Tang in treating primary hyperlipidemia.Methods Ninetyfour patients with primary hyperlipidemia treated in Jiangmen People's Hospital from August 2022 to April 2023 were selected and randomly divided into a control group and a study group,with 47 patients in each group.Patients in the control group were treated with atorvastatin,and those in the study group were treated with Hongqu Tiaozhi Tang,all for 4 weeks.The clinical efficacy after treatment,triglyceride,total cholesterol,highdensity lipoprotein cholesterol,and lowdensity lipoprotein cholesterol levels before and after treatment,the drug safety during treatment,and the occurrence of adverse cardiovascular events during oneyear followup were compared between the two groups.Results The total effective rate of clinical treatment in the study group was 95.74%,which was significantly higher than 78.72%of the control group(P<0.05).Before treatment,there was no significant difference in blood lipid levels between the two groups(P>0.05).After treatment,the levels of triglyceride,total cholesterol,lowdensity lipoprotein cholesterol in both groups were decreased,and the levels of highdensity lipoprotein cholesterol were elevated;the levels of triglyceride,total cholesterol,lowdensity lipoprotein cholesterol in the study group were(1.52±0.22)mmol/L,(4.03±0.55)mmol/L,and(2.24±0.35)mmol/L,which were significantly lower than(1.86±0.35)mmol/L,(4.87±0.62)mmol/L,and(2.87±0.39)mmol/L in the control group;the level of highdensity lipoprotein cholesterol was(1.42±0.13)mmol/L,which was significantly higher than(1.29±0.14)mmol/L of control group;the differences were statistically significant(P<0.05).The total incidence of adverse drug reactions in the study group was 6.38%,which was significantly lower than 23.40%in the control group(P<0.05).During the followup of one year,the total incidence of adverse cardiovascular events in the study group was 8.51%,which was significantly lower than 25.53%in the control group(P<0.05).Conclusion Hongqu Tiaozhi Tang can effectively regulate the blood lipid level of patients and reduce the incidence of adverse cardiovascular events in the treatment of primary hyperlipidemia,with significant clinical treatment effect and high safety.